Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Neuroendocrine cancer

Surufatinib — a novel oral agent for neuroendocrine tumours

Nature Reviews Endocrinology volume 17, pages 9–10 (2021)Cite this article

Subjects

In two phase III trials, surufatinib, a novel oral tyrosine kinase inhibitor targeting immune cells and angiogenesis, was effective for treating pancreatic and extra-pancreatic neuroendocrine tumours. These findings further expand the therapeutic options for patients with gastro–entero–pancreatic, thymic and lung neuroendocrine tumours.

Refers to Xu, J. et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30493-9 (2020). | Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30496-4 (2020).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hofland, J., Kaltsas, G. & de Herder, W. W. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr. Rev. 41, 371–403 (2020).

    Article  Google Scholar 

  2. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).

    Article  CAS  Google Scholar 

  3. Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968–977 (2016).

    Article  CAS  Google Scholar 

  4. Cai, L. et al. Role of tumor-associated macrophages in the clinical course of pancreatic neuroendocrine tumors (PanNETs). Clin. Cancer Res. 25, 2644–2655 (2019).

    Article  CAS  Google Scholar 

  5. Lyons, Y. A. et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget 8, 96496–96505 (2017).

    Article  Google Scholar 

  6. Xu, J. et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial. Clin. Cancer Res. 25, 3486–3494 (2019).

    CAS  PubMed  Google Scholar 

  7. Xu, J. M. et al. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget 8, 42076–42086 (2017).

    Article  Google Scholar 

  8. Xu, J. et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30493-9 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30496-4 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Dasari, A. et al. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs). J. Clin. Oncol. 38, 4610–4610 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Oncology Unit, Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

    Anna Koumarianou

  2. ENETS Center of Excellence, National and Kapodistrian University of Athens, Athens, Greece

    Anna Koumarianou & Gregory Kaltsas

  3. First Department of Propaedeutic and Internal Medicine, Endocrine Unit, National and Kapodistrian University of Athens, Athens, Greece

    Gregory Kaltsas

Authors
  1. Anna Koumarianou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Kaltsas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory Kaltsas.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koumarianou, A., Kaltsas, G. Surufatinib — a novel oral agent for neuroendocrine tumours. Nat Rev Endocrinol 17, 9–10 (2021). https://doi.org/10.1038/s41574-020-00439-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-020-00439-0

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing